Tetrapyrroles and derivatives
Abcam 4-Thiouridine, RNA synthesis inhibitor, 5MG
MW 260.27 Da, Purity >99%. Ribonucleoside (Uridine ab143255) analog. Antisense agent. RNA synthesis inhibitor. Modifies oligos slated for RNA. Induces p53 and inhibits proliferation. Metabolically labels RNA for stability studies.
The product is subject to the following: Abcam Restricted Use Statement
Abcam C59, Wnt Antagonist, Wnt signaling pathway inhibitor, 5MG
MW 379.5 Da, Purity >97%. Potent Wnt signaling pathway inhibitor. Inhibits porcupine (PORCN) required for Wnt palmitoylation, secretion, and biological activity. Inhibits Wnt-mediated transcription (IC₅₀ = 74 pM) and cell proliferation. Active in vivo..
The product is subject to the following: Abcam Restricted Use Statement
Abcam Lactacystin, proteasome inhibitor, 200UG
MW 376.4 Da, Purity >95%. Potent, irreversible, cell-permeable, selective 20S proteasome inhibitor (IC₅₀ = 70 nM). Inhibits cell-cycle progression and induces neurite outgrowth in vitro. Anti-bacterial and antitumor agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Jasplakinolide, Actin polymerization and stabilization inducer, 50UG
MW 709.7 Da, Purity >95%. Cell-permeable actin polymerization and stabilization inducer. Potent antiproliferative activity (IC₅₀ = 15 nM). Antitumor and antifungal agent. Active in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dorsomorphin (Compound C), AMP-kinase inhibitor, 5MG
MW 399.5 Da, Purity >99%. Potent, selective and reversible inhibitor of AMP-kinase (Ki = 109 nM). Inhibits AMPK activation induced by AICAR (ab120358) and metformin (ab120847). Selective inhibitor of bone morphogenetic protein (BMP) type I receptors (ALK2, ALK3 and ALK6). Does not affect ZAPK, SYK, PKCθ, PKA and JAK3. Cell-permeable. Also available in a water soluble form (Dorsomorphin dihydrochloride - ab144821).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 242084 hydrochloride, 5-HT2C antagonist, 10MG
MW 431.3 Da, Purity >98%. Potent, selective 5-HT2C antagonist (pKi values are 9 (5-HT2C), 7 (5-HT2B), 6.8 (5-HT2A), 6.4 (5-HT1A), 6.4 (5-HT1B), 6.4 (5-HT1D), 6 (5-HT1E), <6.1 (5-HT1F), <5.5 (5-HT4), 6 (5-HT6), 6.1 (5-HT7), 6.2 (D2), 6.2 (D3) and <5 (α1)). Blood-brain barrier permeable. Anxiolytic activity *in vivo*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WAY-100635 maleate, 5-HT1A receptor antagonist, 10MG
MW 538.6 Da, Purity >98%. Potent, selective, silent 5-HT1A receptor antagonist (IC50 = 1.35 nM). Displays >100-fold selectivity for 5-HT1Arelative to a range of other CNS receptors including other 5-HT subtypes, adrenoceptors, dopamine, GABA, histamine and ion channels. Binds selectively to rodent brain 5-HT1A receptors *in vivo* (iv admin). Unlike WAY100135, WAY100635 displays no partial agonist activity in the ventral hippocampus of rats.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Endothelin-1 (human, porcine), Vasoconstrictor peptide, 500UG
MW 2491.9 Da. Endothelin-1 (human, porcine), Vasoconstrictor peptide. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam UDP-glucose, Highly P2Y14 agonist, 1G
MW 610.27 Da. Highly potent, endogenous P2Y14 agonist (EC50 = 82 nM). Involved in modulation of gastric function. UDP also available (ab120383).
The product is subject to the following: Abcam Restricted Use Statement
Abcam omega-Agato x in IVA, Ca2+ channel blocker (P and Q type), 10UG
MW 5202 Da. omega-Agatoxin IVA, Ca2+ channel blocker (P and Q type). Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Rebo x etine mesylate, Noradrenaline reuptake inhibitor, 10MG
MW 409.5 Da, Purity >99%. Potent, selective noradrenaline reuptake inhibitor, with high selectivity over dopamine and 5-HT transporters. Antidepressant in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dihydrokainic acid, EAAT2 (GLT-1) inhibitor, 1MG
MW 215.25 Da. Selective, non-transportable inhibitor of glutamate transporter EAAT2 (GLT-1) (Ki = 23 μM). 130-fold selective over EAAT1 and EAAT3 (Ki > 3 mM).
The product is subject to the following: Abcam Restricted Use Statement
TARGETMOL CHEMICALS INC GUACETISAL 5MG
Also available in 1 mg 2 mg 10 mg 25 mg 50 mg 100 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Guacetisal is extracted from the esterification reaction of acetylsalicylic acid with guaiacol which can be used for research on the treatment of chronic bronchitis. purity: 98%
Abcam LY 294002, PI3-kinase inhibitor, 1MG
MW 307.3 Da, Purity >99%. A highly selective inhibitor of phosphatidylinositol 3-kinase (IC₅₀ = 1.4 μM). Selective over a range of other kinases including protein kinase C, protein kinase A, MAPK and PI4- kinase (IC₅₀ > 50 μM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dihydrokainic acid, EAAT2 (GLT-1) inhibitor, 10MG
MW 215.25 Da. Selective, non-transportable inhibitor of glutamate transporter EAAT2 (GLT-1) (Ki = 23 μM). 130-fold selective over EAAT1 and EAAT3 (Ki > 3 mM).
The product is subject to the following: Abcam Restricted Use Statement